Most Recent

• Modernizing manufacturing through a connected shop floor

  By Michael Jovanis, vice president, Vault Quality, Veeva Systems

  The shop floor is ripe for digital transformation. Manufacturing operations are still mostly paper-based, with aging systems also in use long past their shelf life. Adapting to new processes, manufacturing or training methods, or production requirements is difficult because processes are manual and…

  Full Story

• A dose of Washington comes to CPhI in Chicago

  By Meagan Parrish, Senior Editor

  Sen. Jeff Flake (R-Arizona) During his keynote address to a packed auditorium inside CPhI North America in Chicago this April, it became clear that Sen. Jeff Flake (R-Arizona) is one of the last of a dying breed. While combative politics continue to create gridlock inside the nation’s capital,…

  Full Story

• Joint ventures in pharma (and nature)

  By Karen Langhauser, Chief Content Director

  Often, symbiotic relationships come naturally. I recently learned (via Animal Planet at 1 a.m.) that coyotes and badgers are frequently seen hunting together. This struck me as bizarre, as the two animals are generally competing for the same meal.“Don’t be fooled,” said the narrator, “these…

  Full Story

• Pharma's budding opportunity

  By Meagan Parrish, Senior Editor

  No single molecule has likely ever generated as much buzz in the wellness market as CBD.Cannabidiol — commonly known as CBD — is one of the primary, non-psychoactive compounds found in the cannabis plant. A recent loosening of regulations for CBD has triggered an explosion of over-the-counter…

  Full Story

• Solid Dose: Under-hyped but not under-represented

  By Karen Langhauser, Chief Content Director

  Tablets may not be as glamorous or cutting-edge as emerging sectors of the biologics markets, but they have their upsides. Oral solid dose formulations are efficient and cost-effective to manufacture, shelf stable and easy to administer. Perhaps most importantly, they are understood and accepted by…

  Full Story

• The future is transparent

  By Pierre-François Thaler Co-Founder and Co-CEO, EcoVadis

  It’s no doubt an interesting time for pharma. Competition is fierce in the tight race for new drug discovery. Many leading companies are merging and acquiring where they can to fill gaps in product portfolios and R&D and more importantly, gain access to new markets — especially the U.S.,…

  Full Story